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The unconventional myosin Myo1c has been impli-
cated in insulin-regulated GLUT4 translocation to
the plasma membrane in adipocytes. We show that
Myo1c undergoes insulin-dependent phosphoryla-
tion at S701. Phosphorylation was accompanied by
enhanced 14-3-3 binding and reduced calmodulin
binding. RecombinantCaMKII phosphorylatedMyo1c
in vitro and siRNA knockdown of CaMKIId abolished
insulin-dependent Myo1c phosphorylation in vivo.
CaMKII activity was increased upon insulin treatment
and the CaMKII inhibitors CN21 and KN-62 or the
Ca2+ chelator BAPTA-AMblocked insulin-dependent
Myo1c phosphorylation and insulin-stimulated glu-
cose transport in adipocytes. Myo1c ATPase activity
was increased after CaMKII phosphorylation in vitro
and after insulin stimulation of CHO/IR/IRS-1 cells.
Expression of wild-type Myo1c, but not S701A or
ATPase dead mutant K111A, rescued the inhibition
of GLUT4 translocation by siRNA-mediated Myo1c
knockdown. These data suggest that insulin
regulates Myo1c function via CaMKII-dependent
phosphorylation, and these events play a role in
insulin-regulated GLUT4 trafficking in adipocytes
likely involving Myo1c motor activity.
INTRODUCTION
Insulin increases glucose uptake intomuscle and fat cells by trig-
gering the translocation of the facilitative glucose transporter
GLUT4 from intracellular storage vesicles (GSVs) to the plasma
membrane (PM). This involves multiple steps, each of which
invokes the activity of numerous proteins. For example, the bio-
genesis of GSVs involves coat proteins and other factors (Millar
et al., 1999); the storage of these vesicles reportedly involves
sequestration factors (Yu et al., 2007); the movement of GSVs
to the cell periphery involves motor proteins and microtubules
(Olson et al., 2001; Tong et al., 2001); once at the cell periphery
the GSVs specifically interact with the plasma membrane in
a multistage process involving tethering factors such as the384 Cell Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevierexocyst followed by SNARE-mediated docking and fusion (Inoue
et al., 2003; Kanzaki and Pessin, 2001; Martin et al., 1998; Yang
et al., 2001).
Recent progress in defining key insulin-regulated steps has
been derived from two separate approaches: the use of a mem-
brane fusion assay in which some aspects of the process have
been reconstituted in vitro (Koumanov et al., 2005), and the
use of total internal reflection fluorescence microscope (TIRFM),
a high-resolution method for studying events close to the PM in
living cells (Bai et al., 2007; Huang et al., 2007). Both of these
methods indicate that the PM is a major regulatory node for
insulin action. In particular, the latter method dissected the
encounter of GSVs with the PM into multiple steps and showed
that a step downstream of vesicle docking is the major insulin-
regulated step (Bai et al., 2007). This has provided important
information in the search for key molecules that function at the
intersection point between signaling and vesicle transport.
The PI3K/Akt pathway plays a central role in regulating
glucose transport in muscle and fat cells, and so identifying
downstream targets of Akt, particularly those acting at the PM,
is an important goal. One such target is the RabGAP TBC1D4/
AS160, the phosphorylation of which plays an essential yet
incomplete role in GLUT4 trafficking (Sano et al., 2003). Overex-
pression of a TBC1D4 mutant, in which each of the Akt phos-
phorylation sites have been mutated, in adipocytes blocks insu-
lin-stimulated GLUT4 translocation (Sano et al., 2003). However,
using TIRFM it has been shown that the function of TBC1D4 is
most closely linked to GSV docking, which as described above
seems to be a relatively minor insulin-regulated step (Bai et al.,
2007).
One approach to identify phosphoproteins that are activated
in response to a variety of cellular triggers is to use phosphopro-
tein binding domains as affinity matrices as an enrichment step
in combination with mass spectrometry. One such binding inter-
mediate that has been particularly useful in identifying phospho-
proteins, associated with tyrosine kinase signaling pathways is
the 14-3-3 family of proteins (Yaffe et al., 1997). The overlap in the
consensus sites for 14-3-3 protein binding and a number of AGC
kinase family members is very high. 14-3-3 binding has been
exploited previously to identify phosphoproteins from HeLa
cells (Meek et al., 2004; Rubio et al., 2004) and HEK293 cells
(Benzinger et al., 2005; Jin et al., 2004).
We describe here the use of this approach for the identification
of a novel insulin-regulated phosphoprotein in adipocytes, theInc.
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Myo1c Phosphorylation in GLUT4 Translocationunconventional motor protein Myo1c. This is a particularly excit-
ing observation because Myo1c acts principally at the PM, play-
ing an important role in a diverse set of physiological processes
including the translocation of ion channels within themembranes
of stereocilia in vestibular hair cells of the ear (Batters et al., 2004;
Phillips et al., 2006; Stauffer et al., 2005), cytoskeletal rearrange-
ment andmembrane protrusion in neuronal growth cones (Wang
et al., 2003), and antidiuretic hormone-regulated delivery of
sodium channels to the brush border of kidney epithelial cells
(Wagner et al., 2005). Myo1c is also involved in the insulin-
regulated delivery of GLUT4 to the PM in adipocytes (Bose et al.,
2002, 2004). Reduced expression of Myo1c in adipocytes using
siRNAor overexpression of theMyo1c tail domain, as a dominant
inhibitor, both impair insulin stimulated translocation of GLUT4 to
the PM (Bose et al., 2002; Huang et al., 2005).
RESULTS
Identification of Myo1c as a 14-3-3-Interacting Protein
Many downstream targets of insulin, including TBC1D4, GSK3,
and BAD, bind to 14-3-3 upon phosphorylation. To identify
insulin-regulated phosphoproteins in insulin-sensitive cell types
we undertook a comprehensive proteomic analysis of insulin-
regulated 14-3-3-interacting proteins in insulin-sensitive tissues.
14-3-3-interacting proteins were isolated from whole cell lysates
of insulin-treated cells using a 14-3-3b affinity matrix. Interacting
proteins were resolved by SDS-PAGE followed by mass
spectrometry analysis (Figure 1A). Using this strategy we identi-
fied >400 putative 14-3-3-binding proteins from insulin-
stimulated cells (Table S1), 75% of which contain at least one
14-3-3 mode 1 consensus site (RSXpS/TXP) according to the
Scansite program with greater than medium stringency. A
number of known insulin-regulated phosphoproteins including
6-phosphofructo-2-kinase, Bcl2-antagonist of cell death (BAD),
Forkhead in rhabdomyosarcoma (FKHR), glycogen synthase
kinase-3 (GSK-3), insulin receptor substrate 1 (IRS1), PI3K regu-
latory domain p85, tuberous sclerosis 1 and 2 (TSC1-TSC2), and
TBC1D4 (Mackintosh, 2004; Wilker and Yaffe, 2004) were iden-
tified confirming the validity of our 14-3-3 purification approach.
One of the most interesting proteins identified in this screen
was the unconventional myosin Myo1c. The sequence coverage
of Myo1c (Swiss-Prot accession number: MYO1C_MOUSE,
Q9WTI7) purified from the PM was 37.2% compared to only
3.6% from the cytosol, suggesting that the PM is the major loca-
tion where 14-3-3 interacts with Myo1c. This interaction was not
observed in rat muscle tissue, suggesting that this interaction
may be specific to adipocytes. To confirm this interaction endog-
enous Myo1c was immunoprecipitated from 3T3-L1 adipocytes.
Sypro Ruby staining revealed bands of molecular weight 120
kDa and 30 kDa (data not shown). Mass spectrometry analysis
of these bands revealed that they corresponded to Myo1c and
several 14-3-3 isoforms, respectively. This suggests that there
is little 14-3-3 isoform specificity in this interaction.
Insulin Regulates Myo1c Phosphorylation
and 14-3-3 Binding
The unconventional myosin motor protein Myo1c fulfilled many
of our designated criteria. Myo1c is known to play a role in
GLUT4 trafficking in adipocytes (Bose et al., 2002, 2004), andCellit was enriched in the PM fraction (Table S1). The in vitro interac-
tion of Myo1c with 14-3-3 was confirmed by immunoblotting
using a Myo1c specific monoclonal antibody (Figure 1B). Insulin
increased the amount of Myo1c associated with 14-3-3 com-
pared to that observed under basal conditions, and this effect
was abolished by the PI3K inhibitor Wortmannin. Similar data
were obtained when EYFP-tagged Myo1c, and GST-tagged
14-3-3b were coexpressed in CHO/IR/IRS-1 cells, indicating
that the insulin-dependent association of Myo1c and 14-3-3
occurs in vivo (Figure 1C). One possible explanation for the insu-
lin-dependent interaction between Myo1c and 14-3-3 is that
Myo1c may interact with another protein that is phosphorylated
in response to insulin. To exclude this possibility, we performed
a GST-overlay assay using GST-14-3-3 (Figure 1D). EYFP-
Myo1c was immunoprecipitated from CHO/IR/IRS-1 cells, sub-
jected to SDS-PAGE, and transferred to PVDF membrane and
incubated with GST-14-3-3. There was a direct association
between 14-3-3 and Myo1c using this approach, and we
observed increased binding of 14-3-3 to Myo1c isolated from
insulin-treated cells compared to non-insulin-treated cells. To
prove that this interaction was due to Myo1c phosphorylation,
the PVDF membrane was incubated with alkaline phosphatase
prior to the overlay, and this completely abolished the interac-
tion. These findings demonstrate that insulin stimulates Myo1c
phosphorylation in adipocytes, resulting in its interaction with
14-3-3 proteins.
Myo1c Is Phosphorylated on S701 in Response to Insulin
Analysis of the Myo1c primary amino acid sequence by either
Scansite and Phospho-MAP identified multiple potential phos-
phorylation and 14-3-3-binding sites. Site-directed mutagenesis
was used to map putative phosphorylation sites in Myo1c. Res-
idues S142, T564, and S701were initially chosen for site directed
mutagenesis. S142 has a high stringency mode 2 consensus
14-3-3-binding motif (RXXXpS/TXP), T564 and S701 were iden-
tified as potential mode 1 consensus 14-3-3-binding motifs
(RSXpS/TXP); and T564 is also a potential Akt phosphorylation
motif. Each of these sites was mutated to Ala, and mutants
were expressed in CHO/IR/IRS-1 cells. As shown in Figure 1E,
Myo1c WT and the S142A and T564A mutants interacted to
a similar extent with 14-3-3 in an insulin-regulated manner. How-
ever, mutation of S701 completely inhibited the 14-3-3/Myo1c
interaction. Based on these data, we conclude that S701 is the
major insulin-regulated phosphorylation site in Myo1c that
regulates 14-3-3 binding.
The Role of Myo1c Phosphorylation
in Calmodulin Binding
It is of interest that S701 is located at the start of the Myo1c neck
domain proximal to the four calmodulin-binding IQ motifs (Fig-
ure 2A). Increased calcium displaces calmodulin from one or
more of these IQ domains (Gillespie and Cyr, 2002), and so we
reasoned that phosphorylation may play a role in calmodulin
binding. Phosphorylation at S701 may either affect calmodulin
binding to IQ1 or calmodulin binding may regulate Myo1c phos-
phorylation at S701. To test these possibilities, we generated an
IQ1A mutant, in which four of the five residues of the IQ consen-
sus sequence of IQ1 were mutated to Ala (Figure 2A). This
mutation was previously shown to prevent calmodulin bindingMetabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc. 385
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(A) 14-3-3-pulldown from 3T3-L1 adipocytes. 3T3-L1 adipocytes were stimulated with 100 nM insulin for 30 min, and lysates were incubated with 14-3-3 sephar-
ose beads overnight; beads were washed and bound proteins eluted with SDS-PAGE sample buffer followed by separation of the proteins by SDS-PAGE. 14-3-3
sepharose without incubation with lysate was used as control. To detect total protein, the gel was silver stained.
(B) In vitro association of 14-3-3 and Myo1c in 3T3-L1 adipocytes. Cell lysate from either basal, insulin-treated, or Wortmannin/insulin-treated (100 nMWortman-
nin for 10 min prior to insulin stimulation) 3T3-L1 adipocytes was subjected to 14-3-3 pulldown. Input cell extracts and pulldowns were analyzed by western blot
with the use of anti-Myo1c and anti-14-3-3 antibodies. The experiment was performed three times, and the images are from a representative experiment.386 Cell Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc.
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was observed between calmodulin and Myo1c WT in nonstimu-
lated cells, whereas this interaction was reduced by 45%
following insulin stimulation (p < 0.05 versus basal; Figure 2B).
Mutation of the IQ1 domain resulted in a 31% reduction in cal-
modulin binding to Myo1c (p < 0.05 versus WT/basal) compared
to WT Myo1c. The fact that calmodulin binding was not com-
pletely ablated in the IQ1 mutant suggests that this domain is
not required for calmodulin binding to the adjacent IQ domains.
Whereas calmodulin binding to WT Myo1c was reduced with
insulin, this was not observed for the S701A and IQ1A mutants
(Figure 2B). This suggests that Myo1c S701 phosphorylation
and calmodulin binding to IQ1 are mutually exclusive events,
raising the question of whether phosphorylation regulates
calmodulin binding or vice versa. If calmodulin binding to IQ1
is required for Myo1c phosphorylation, then the IQ1A mutant
should display reduced insulin-stimulated phosphorylation and
14-3-3 binding. However, dissociation of calmodulin from IQ1
neither inhibited nor stimulated phosphorylation at S701 (Fig-
ure 2C). In contrast, insulin did not stimulate 14-3-3 binding to
the double mutant S701AIQ1A, which contains both the phos-
phorylation site mutation and the IQ1 mutation. These results
suggest that calmodulin binding to IQ1 is not required for phos-
phorylation at S701. Although insulin may also regulate calmod-
ulin binding to other IQ domains, these data suggest that insulin
inhibits calmodulin binding to the first IQ domain in Myo1c via
phosphorylation at S701.
Calcium/Calmodulin-Dependent Protein Kinase II
(CaMKII) Phosphorylates Myo1c
We next sought to identify the Myo1c kinase. In silico analysis
revealed S701 is a potential phosphorylation site for PKA,
PKC, and CaMKII. As shown in Figure 3A, the PKCz pseudosub-
strate and the Akt inhibitor had no significant effect on insulin-
stimulated 14-3-3 binding to Myo1c. In contrast, Wortmannin
and KN-62 caused a substantial reduction in the amount of
14-3-3 coimmunoprecipitated with Myo1c from insulin-treated
3T3-L1 adipocytes (Figure 3B). To confirm the role of CaMKII
in Myo1c phosphorylation, we utilized a highly specific cell-
penetrating CaMKII inhibitor tat-CN21 (Vest et al., 2007). The
insulin-stimulated interaction between 14-3-3 and Myo1c was
significantly inhibited by tat-CN21, whereas the control peptide,
tat-ctrl, was without effect (Figure 3C). To confirm the status of
endogenous Myo1c phosphorylation, 3T3-L1 adipocytes wereCell Mlabeled to equilibrium with [32P]orthophosphate, andMyo1c was
immunoprecipitated following incubation of cells with or without
kinase inhibitors and insulin. Insulin increased the amount of
phosphorylated Myo1c in adipocytes in a Wortmannin and tat-
CN21-sensitive manner (Figure 3D), consistent with the in vitro
14-3-3 pulldown data.
CaMKII is activated in vivo by increased cytosolic calcium,
which triggers calmodulin binding to CaMKII. KN-62 prevents
the activation of CaMKII by inhibiting calmodulin binding (Toku-
mitsu et al., 1990). Intriguingly, chelation of cytosolic calcium
with BAPTA-AM inhibits insulin-stimulated glucose transport
and GLUT4 translocation in adipocytes (Whitehead et al., 2001).
Hence, we next set out to establish if BAPTA-AM inhibits insulin-
stimulated Myo1c phosphorylation and 14-3-3 binding. BAPTA-
AM almost completely inhibited insulin-stimulated Myo1c
phosphorylation as indicated by impaired binding to 14-3-3
(Figure 3E). Conversely, the Ca2+ ionophore A23187 increased
14-3-3 binding to Myo1c to a similar extent as insulin (Figure 3F).
To further investigate the role of CaMKII in phosphorylation of
Myo1c, we utilized an siRNA construct targeting CaMKIId, a
major isoform expressed in 3T3-L1 adipocytes (Figure 3G).
Reduction of CaMKIId protein expression by 90% percent
resulted in a significant reduction in insulin-stimulated Myo1c
binding to 14-3-3, whereas in cells transfected with a control
siRNA we observed an 2.5-fold increase in Myo1c binding to
14-3-3 with insulin. Based on these results, we propose that
CaMKII mediates the insulin-stimulated phosphorylation of
Myo1c at S701.
Next, we performed an in vitro phosphorylation assay using
recombinant CaMKII and endogenous Myo1c immunoprecipi-
tated from 3T3-L1 adipocytes. An insulin-dependent and
KN-62-sensitive Myo1c/14-3-3 interaction was observed in the
absence of recombinant CaMKII (Figure 3H). Incubation with
active CaMKII, but not inactive CaMKII, enhanced Myo1c/
14-3-3-binding under all conditions. Moreover, CaMKII phos-
phorylation of Myo1c in vitro was sensitive to the CaMKII inhib-
itor tat-CN21, but not to the control peptide tat-ctrl (Figure 3I).
To confirm that CaMKII phosphorylates Myo1c directly on
S701, EYFP-Myo1c WT and the S701A mutant were immuno-
precipitated from CHO/IR/IRS-1 cells and incubated with
recombinant CaMKII in the presence of [g32P]ATP. Phosphoryla-
tion of Myo1c WT but not the Myo1c S701A mutant was ob-
served with CaMKII (Figure 3J). Hence, we conclude that CaMKII
phosphorylates Myo1c both in vitro and in vivo at S701, and(C) In vivo association of 14-3-3 and Myo1c in CHO/IR/IRS-1 cells. CHO/IR/IRS-1 cells were transiently cotransfected with EYFP-Myo1c and GST-14-3-3b. Cell
lysate from either basal, insulin-treated, or Wortmannin/insulin-treated (100 nM Wortmannin for 10 min prior to insulin stimulation) CHO/IR/IRS-1 cells were
subjected to pulldown with glutathione sepharose or immunoprecipitation with anti-GFP antibody. Input cell extracts, pulldowns, and immunoprecipitates
were analyzed by western blot with the use of anti-GFP and anti-GST antibodies to detect EYFP-Myo1c and GST-14-3-3b, respectively. The experiment was
performed three times and the images are from a representative experiment.
(D) Direct and phosphorylation-dependent association of 14-3-3 and Myo1c. CHO/IR/IRS-1 cells were transiently transfected with EYFP-Myo1c. Cell
lysate from either basal or insulin-treated cells was subjected to immunoprecipitation with anti-GFP and IgG antibodies. Input cell extracts and
immunoprecipitates were analyzed by western blotting with the use of anti-GFP antibody (upper panel). The PVDF membrane containing immunoprecipitated
Myo1c was incubated with or without alkaline phosphatase in phosphatase buffer overnight at 37C. The membrane was probed for binding to either GST
or GST-14-3-3 with the use of anti-GST antibody (lower panel). The experiment was performed three times, and the images are from a representative
experiment.
(E) Mapping Myo1c phosphorylation sites. CHO/IR/IRS-1 cells were transiently transfected with either EYFP (empty vector), EYFP-Myo1cWT, S142A, T564A,
or S701A. Cell lysates from either basal or insulin-treated cells were subjected to 14-3-3 pulldown. Input cell extracts and pulldowns were analyzed by western
blot with the use of anti-GFP antibody, which detects EYFP-Myo1c, and anti-14-3-3 antibody. The experiment was performed three times, and the images are
from a representative experiment.etabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc. 387
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dependent pathways.
To determine if CaMKII activity may regulate the insulin-
dependent dissociation of calmodulin and Myo1c as shown
earlier (Figure 2B), we pretreated adipocytes with KN62 or
tat-CN21. Both compounds, as well as Wortmannin, inhibited
the insulin-dependent reduction of calmodulin binding to Myo1c
(Figure 3K).
Insulin Induces CaMKII Phosphorylation and Activation
in Adipocytes
CaMKII is activated following autophosphorylation at T286 (Col-
bran et al., 1988).We next sought to determine if insulin activates
CaMKII in adipocytes using an anti-pT286 CaMKII antibody.
Phosphorylated CaMKII was detected in unstimulated cells,
and insulin increased CaMKII phosphorylation in a dose- and
Figure 2. Phosphorylation of Myo1c on S701 Regu-
lates Calmodulin Binding
(A) Domain structure of Myo1c. Myo1c consists of three
domains including head, neck, and tail domain. S701A,
IQ1A, and S701AIQ1A double mutants were generated in this
study. S701A contains a single amino acid change at S701,
while IQ1A contains four amino acid mutations (I706A,
Q707A, R711A, and G712A).
(B) In vivo association of different Myo1cmutants and calmod-
ulin in CHO/IR/IRS-1 cells. CHO/IR/IRS-1 cells were tran-
siently transfected with either EYFP-Myo1cWT, S701A, IQ1A,
or EYFP (empty vector). Cell lysates from either basal or
insulin-treated cells were subjected to immunoprecipitation
with anti-GFP antibody. Input cell extracts and pulldowns
were analyzed by western blot with the use of anti-GFP anti-
body, which detects EYFP-Myo1c, and anti-CaM antibody.
The experiment was performed three times, and the images
are from a representative experiment.
(C) In vitro association of different Myo1c mutants and 14-3-3
in CHO/IR/IRS-1 cells. CHO/IR/IRS-1 cells were transiently
transfected with either EYFP (empty vector), EYFP-Myo1c
WT, S701A, IQ1A, or S701AIQ1A double mutant. Cell lysates
from either basal or insulin-treated cells was subjected to
14-3-3 pulldown. Input cell extracts and pulldowns were
analyzed by western blot with the use of anti-GFP antibody,
which detects EYFP-Myo1c, and anti-14-3-3 antibody. The
experiment was performed three times, and the images are
from a representative experiment.
time-dependent manner (Figures 4A and 4B). We
also observed increased CaMKII kinase activity
following incubation of adipocytes with insulin
(Figure 4C). These data indicate that CaMKII is ac-
tivated by insulin in 3T3-L1 adipocytes. Moreover,
KN-62 and tat-CN21 inhibited insulin-stimulated
glucose transport by 63% and 46%, respectively
(Figure 4D), consistent with an important role for
this kinase in insulin action.
CaMKII-Dependent Phosphorylation
Increases Myo1c ATPase Activity
As the myosin motor family is responsible for actin-
based motility, we next examined the role of phos-
phorylation on Myo1c ATPase activity. Endoge-
nous Myo1c was immunoprecipitated from basal adipocytes
and incubated with recombinant CaMKII. CaMKII was removed
and Myo1c-bound sepharose was extensively washed with re-
action buffer. [g32P]ATP hydrolysis was assayed in the presence
of tat-CN21 to abolish the activity of any remaining CaMKII. An
equivalent amount of Myo1c was present in all conditions (Fig-
ure 5A). CaMKII, but not inactive CaMKII, stimulated Myo1c
ATPase activity by 3- to 4-fold (Figures 5A and 5B). Inclusion
of GST-14-3-3 in this assay had no further effect on Myo1c
ATPase activity. We next explored if insulin stimulation affects
Myo1c ATPase activity in vivo by measuring the ATPase activity
of EYFP-Myo1c WT immunoprecipitated from transiently trans-
fected CHO/IR/IRS-1 cells with or without insulin stimulation.
Insulin increased the ATPase activity of Myo1c WT by 2-fold
(Figures 5C and 5D), whereas a Myo1c ATPase mutant (EYFP-
Myo1c K111A), only showed background hydrolysis of ATP,388 Cell Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc.
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shown). These data suggest that insulin-stimulated phosphory-
lation of Myo1c regulates its motor activity and 14-3-3 binding
does not appear to play a significant role in this effect at least
in vitro.
CaMKII-Dependent Phosphorylation of Myo1c
Regulates GLUT4 Translocation
We next set out to establish if Myo1c phosphorylation plays
a role in GLUT4 translocation using a knockin approach. An
siRNA construct was designed to target the untranslated
region of Myo1c mRNA. Expression of this siRNA in adipo-
cytes resulted in a substantial reduction in endogenous
Myo1c levels (85%) (Figure 6A). In agreement with previous
studies (Bose et al., 2002), siRNA-mediated reduction in
Myo1c in adipocytes significantly reduced insulin-stimulated
GLUT4 translocation in 3T3-L1 adipocytes (Figure 6B). Re-
expression of WT Myo1c in cells expressing the Myo1c siRNA
rescued the block in GLUT4 translocation (Figures 6C and 6D).
Strikingly, re-expression of the Myo1c S701A mutant was un-
able to rescue the defect in insulin-stimulated GLUT4 trans-
location observed in cells expressing the Myo1c siRNA. These
data indicate that Myo1c phosphorylation at S701 plays an
essential role in insulin-stimulated GLUT4 translocation in vivo.
As described above, insulin-dependent Myo1c phosphoryla-
tion/14-3-3-binding triggers release of calmodulin from the first
and possibly additional IQ domains in Myo1c. Hence, this raises
the question of whether phosphorylation of Myo1c per se plays
an essential role in insulin action or if the major effect is mediated
via calmodulin release. To explore this relationship in more
detail, we first examined the consequences of reintroducing
the Myo1c calmodulin-binding mutant into adipocytes lacking
endogenous Myo1c (Figure 6C). Intriguingly, upon insulin stimu-
lation of cells expressing the IQ1A mutant insulin-stimulated
GLUT4 translocation was partially restored. However, since
calmodulin is not displaced from the Myo1c S701A mutant in
response to insulin (Figure 2B), this is consistent with a possible
role for both phosphorylation/14-3-3 binding and calmodulin re-
lease in the function of Myo1c in insulin-mediated GLUT4 trans-
location. To further elucidate the importance of both steps, we
used the S701AIQ1A double mutant. If phosphorylation/14-3-3
binding simply regulates Myo1c function via displacement of
calmodulin, then the S701AIQ1A mutant should phenocopy the
IQ1A mutant. Intriguingly, that was not the case pointing toward
a role of phosphorylation/14-3-3 independent of calmodulin
displacement as the important insulin-regulated step. Notably,
expression of the IQ1A mutant in adipocytes resulted in a signif-
icant increase in non-insulin-dependent GLUT4 translocation
(Figure 6D). As shown in Figure 2C, this mutant does not display
increased phosphorylation under basal conditions, suggesting
that regulated calmodulin binding to Myo1c per se may play an
additional role in this process. Hence, these data suggest that
both calmodulin binding in the basal state and phosphorylation
after insulin-stimulation may regulate the function of Myo1c in
GLUT4 translocation.
To explore the relationship between Myo1c ATPase activity
and GLUT4 translocation in adipocytes, we reintroduced the
ATPase catalytic domain mutant in Myo1c knockdown adipo-
cytes. Re-expression of Myo1c K111A was unable to rescueCellthe defect in insulin-stimulated GLUT4 translocation mediated
by knockdown of Myo1c (Figures 6C and 6D). This suggests
that Myo1c ATPase activity is required for insulin-stimulated
GLUT4 translocation in adipocytes.
DISCUSSION
In the present study we show that the myosin motor Myo1c
undergoes increased phosphorylation in response to insulin. In
view of the important role of Myo1c in GLUT4 trafficking (Bose
et al., 2002), this represents a key advance in this area. Insulin
stimulates Myo1c phosphorylation at a site that flanks one of
its major calmodulin-binding domains. Insulin-dependent
Myo1c phosphorylation is regulated by CaMKII in a PI3K-depen-
dent manner resulting in reduced calmodulin binding to Myo1c
and concomitant association with 14-3-3 proteins. The observa-
tion that the Myo1c IQ1A mutant undergoes normal insulin-
dependent phosphorylation suggests that calmodulin binding
to the first IQ domain is not required for Myo1c phosphorylation,
excluding the possibility that this domain is required for CaMKII
binding. Further studies are required to determine if the addi-
tional IQ domains are required for CaMKII-dependent Myo1c
phosphorylation. Notwithstanding, our data suggest a role for
Myo1c phosphorylation in calmodulin release. Phosphorylation
has been shown to play an important role in calmodulin binding
to other IQ domain proteins. Serine phosphorylation of neuromo-
dulin at a variable residue within its consensus IQ domain
(IQxpSxRGxxxR) regulates calmodulin binding (Chapman
et al., 1991). A crystal structure of the IQ domains from MyoV
and apo-Calmodulin reveals a role for acidic residues in calmod-
ulin in this interaction (Houdusse et al., 2006). Hence, the intro-
duction of an additional negative charge in this vicinity as in
phosphorylated Myo1c would likely impair this interaction
(pSxxxxIQxxxRGxxxR). Alternatively, binding of 14-3-3 upon
phosphorylation could lead to steric displacement of calmodulin.
How could Myo1c phosphorylation and/or regulated calmod-
ulin binding play a role in the function of this molecule? It has
been reported that calmodulin binding to Myo1c inhibits its ac-
tin-stimulated ATPase activity and Myo1c ATPase activity is
stimulated by calcium (Barylko et al., 1992; Chacko et al., 1994;
Zhu et al., 1996, 1998). In the present study we show that
CaMKII-mediated phosphorylation stimulates Myo1c ATPase
activity. Hence, this leads to a model where insulin may regulate
the mechanical properties of Myo1c via Ca2+/CaMKII-depen-
dent phosphorylation. To formally test this hypothesis it will be
necessary to precisely identify the consequences of Ca2+
loading and phosphorylation on Myo1c function in vivo. It is
also conceivable that insulin-dependent Myo1c phosphorylation
and 14-3-3 binding may regulate the association of other
proteins, such as cargo, since 14-3-3 possesses at least two
phosphopeptide binding sites.
Another possibility is that phosphorylation may regulate the
association of Myo1c with the PM. Myo1c and Myo1c orthologs
bind to anionic phospholipids (Barylko et al., 2005) via a PIP2
binding site located in the Myo1c tail domain (Hokanson et al.,
2006; Reizes et al., 1994). Consistent with a potential role for
calmodulin binding in the membrane association of Myo1c,
Tang and colleagues (Tang et al., 2002) showed that Ca2+ regu-
lates the binding affinity of Myo1c to lipids. This poses a potentialMetabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc. 389
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Myo1c Phosphorylation in GLUT4 Translocationmodel where Myo1c phosphorylation at S701 may stabilize
membrane association of Myo1c. Intriguingly, we did not
observe a significant reduction in insulin-stimulated CaMKII
phosphorylation in adipocytes at T286 using the PI3K inhibitor
Wortmannin, suggesting that activation of CaMKII by insulin is
PI3K independent. However, insulin-stimulated phosphorylation
of Myo1c was PI3K dependent. This raises the possibility that
PI3K may regulate the accessibility of Myo1c to CaMKII in vivo
either by regulating membrane association of Myo1c or CaMKII
itself. Noteably, CaMKII phosphorylation is regulated via
dynamic subcellular localization of both substrate and kinase
(Tsui et al., 2005). Further studies are required to resolve these
aspects of Myo1c regulation by Ca2+, CaMKII, and PI3K.CeAnother intriguing element of the present study is the role of
CaMKII and Ca2+ in insulin-regulated glucose transport. Al-
though controversial, inhibition of this process using Ca2+ chela-
tors (Whitehead et al., 2001) and CaMKII inhibitors has been
described (Brozinick et al., 1999; Konstantopoulos et al., 2007)
consistent with our data (Figure 4D). The use of inhibitors of
ill-defined specificity, such as KN-62, the inability to document
insulin-dependent changes in cytosolic Ca2+ and CaMKII activ-
ity, and the lack of insulin-regulated CaMKII substrates in adipo-
cytes have provided major obstacles in substantiating the role of
Ca2+ in insulin action. In the present study we have overcome
several of these obstacles by showing that a highly specific
CaMKII inhibitor tat-CN21 inhibits insulin stimulated glucoseFigure 3. CaMKII Phosphorylates Myo1c on S701
(A) Effect of different kinase inhibitors on in vitro 14-3-3 binding of Myo1c. 3T3-L1 adipocytes were pretreated with either 100 nM Wortmannin (W) for 10 min,
50 mMLY294002 (L) for 30 min, 5 mMPKCz pseudosubstrate (P) for 1 hr, 10 mMKN-62 (K) for 45min, or 5 mMAkt inhibitor (A) for 30 min prior to insulin stimulation.
Cell lysate from either basal, insulin-treated, or kinase inhibitors/insulin-treated 3T3-L1 adipocytes was subjected to 14-3-3 pulldown. Input cell extracts and
pulldowns were analyzed by western blot with the use of anti-Myo1c, anti-14-3-3, and anti-pAkt (pS473) antibodies. The experiment was performed three times,
and the images are from a representative experiment.
(B) Effect of Wortmannin and KN-62 on in vivo 14-3-3 binding of Myo1c. 3T3-L1 adipocytes were pretreated with either 100 nMWortmannin for 10 min or 10 mM
KN-62 for 45 min for 30 min prior to insulin stimulation. Cell lysate from either basal, insulin-treated, or kinase inhibitors/insulin-treated 3T3-L1 adipocytes was
subjected to immunoprecipiration using anti-Myo1c antibody and irrelevant antibodies (ctrl-IP). Input cell extracts and immunoprecipitates were analyzed
by western blot with the use of anti-Myo1c and anti-14-3-3 antibodies. The experiment was performed three times, and the images are from a representative
experiment.
(C) Effect of CaM-KIIN-derived peptides, tat-CN21, on in vitro 14-3-3 binding of Myo1c. 3T3-L1 adipocytes were pretreated with either 5 mM tat-CN21 or control
peptide (tat-ctrl) for 30min prior to insulin stimulation. Cell lysate from either basal, insulin-treated, or inhibitor/insulin-treated 3T3-L1 adipocytes was subjected to
14-3-3 pulldown. Input cell extracts and pulldowns were analyzed by western blot with the use of anti-Myo1c and anti-14-3-3 antibodies. The experiment was
performed three times, and the images are from a representative experiment.
(D) In vivo 32P labeling of Myo1c in 3T3-L1 adipocytes. 3T3-L1 adipocytes were labeled with [32P]orthophosphate. Cells were incubated with insulin or kinase
inhibitors as indicated. Cell lysates were subjected to immunoprecipitation with anti-Myo1c and irrelevant antibodies (ctrl-IP). Immunoprecipitates were analyzed
by autoradiography and immunoblottingwith the use of anti-Myo1c antibody. The experiment was performed two times, and the images are from a representative
experiment.
(E) Effect of Ca2+ chelator, BAPTA-AM, on in vitro 14-3-3-binding of Myo1c. 3T3-L1 adipocytes were pretreated with 50 mMBAPTA-AM for 30 min prior to insulin
stimulation. Cell lysate from either basal, insulin-treated, or BAPTA-AM/insulin-treated 3T3-L1 adipocytes was subjected to 14-3-3 pulldown. Input cell extracts
and pulldowns were analyzed by western blot with the use of anti-Myo1c and anti-14-3-3 antibodies. The experiment was performed three times, and the images
are from a representative experiment.
(F) Effect of Ca2+ ionophore, A23187, on in vitro 14-3-3 binding ofMyo1c under basal condition. 3T3-L1 adipocytes were treatedwith 5 mMA23187 for 15min. Cell
lysate from either basal, insulin-treated, or A23187-treated 3T3-L1 adipocytes was subjected to 14-3-3 pulldown. Input cell extracts and pulldowns were
analyzed by western blot with the use of anti-Myo1c and anti-14-3-3 antibodies. The experiment was performed three times, and the images are from a
representative experiment.
(G) Effect of siRNA-mediated CaMKII knockdown on in vitro 14-3-3 binding of Myo1c. 3T3-L1 adipocytes were electroporated with either scrambled or CaMKIId-
targeted siRNA. After 48 hr, cell lysate from either basal or insulin-treated cells was subjected to 14-3-3 pulldown. Input cell extracts and pulldownswere analyzed
by western blot with the use of anti-CaMKII, anti-Myo1c and anti-14-3-3 antibodies. The experiment was performed three times, and the images are from a
representative experiment.
(H) In vitro CaMKII phosphorylation assay of Myo1c. 3T3-L1 adipocytes were either untreated, treated with KN-62 (10 mM for 1 hr) only, insulin only, or pretreated
with KN-62 (10 mM for 45 min) prior to insulin stimulation. Cell lysates were subjected to immunoprecipitation with anti-Myo1c antibody. Input cell extracts were
analyzed by western blot with the use of anti-Myo1c and anti-Actin antibodies (upper panel). The immunocomplex-bound protein G sepharose was incubated
with kinase assay buffer containing either no GST-CaMKII, inactive GST-CaMKII (I), or active GST-CaMKII (A). The kinase reactions were stopped by boiling in
sample buffer, resolved by SDS-PAGE, and transferred to PVDFmembrane. The amounts of GST-CaMKII were detected by western blot with anti-GST antibody.
To detect the amounts of Myo1c immunoprecipitated in each condition, the PVDF membrane containing immunoprecipitated Myo1c was stained with SYPRO
Ruby protein blot stain. The membrane was then probed for binding to GST-14-3-3 with the use of anti-GST antibody to detect the in vitro 14-3-3 binding of
immunoprecipitated Myo1c (lower panel). The experiment was performed three times, and the images are from a representative experiment.
(I) Effect of tat-CN21 on in vitro CaMKII phosphorylation assay of Myo1c. Cell lysate from basal 3T3-L1 adipocytes were subjected to immunoprecipitation with
anti-Myo1c antibody and were subjected to in vitro CaMKII phosphorylation as described in Figure 3H in the presence of [g32P]ATP and either 1 mM tat-CN21 or
1 mM tat-ctrl. Immunoprecipitates were analyzed by autoradiography andWestern blot with the use of anti-Myo1c antibody. The experiment was performed two
times and the images are from a representative experiment.
(J) In vitro CaMKII phosphorylation assay of Myo1c WT and S701A. CHO/IR/IRS-1 cells were transiently transfected with either EYFP (empty vector), EYFP-
Myo1c S701A, or EYFP-Myo1cWT. Cell lysate frombasal CHO/IR/IRS-1 cells were subjected to immunoprecipitationwith anti-GFP antibody andwere subjected
to in vitro CaMKII phosphorylation as described in Figure 3H in the presence of [g32P]ATP. Immunoprecipitates were analyzed by autoradiography and western
blot with the use of anti-GFP antibody. The experiment was performed two times, and the images are from a representative experiment.
(K) Effect of different kinase inhibitors on in vivo calmodulin binding of Myo1c. 3T3-L1 adipocytes were pretreated with either 100 nMWortmannin (W) for 10 min,
10 mM KN-62 (K) for 45 min, or 5 mM tat-CN21 (C) for 30 min prior to insulin stimulation. Cell lysates were subjected to immunoprecipitation using anti-Myo1c
antibody. Input cell extracts and immunoprecipitates were analyzed by western blot with the use of anti-Myo1c and anti-calmodulin antibodies. The experiment
was performed three times, and the images are from a representative experiment.ll Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc. 391
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Myo1c Phosphorylation in GLUT4 TranslocationFigure 4. Insulin Stimulates CaMKII Activation in 3T3-L1 Adipocytes
(A) Dose response of insulin signaling. 3T3-L1 adipocytes were serum-starved and stimulated with insulin at the indicated concentrations for 20 min. The cell
extracts were analyzed by western blot with the use of anti-pCaMKII (T286), anti-pAkt (pS473), and anti-14-3-3 antibodies. The experiment was performed three
times, and the images are from a representative experiment.
(B) Time course of insulin signaling. 3T3-L1 adipocytes were serum-starved and stimulated with 100 nM insulin for 1 to 20min as indicated. The cell extracts were
analyzed by western blot with the use of anti-pCaMKII (T286), anti-pAkt (pS473), and anti-14-3-3 antibodies. The experiment was performed three times, and the
images are from a representative experiment.
(C) In vitro CaMKII kinase activity assay. 3T3-L1 adipocytes were either untreated, treated with insulin, or treated with 5 mM A23187 for 20 min. Cell lysates were
subjected to immunoprecipitation with anti-CaMKII antibody, and the kinase activity assay was preformed directly on the agarose beads by measuring the 32P
labeling of the peptide substrate. The ratio of autonomous activity to maximal activity was calculated for each condition, and the ratio corresponding to the
unstimulated cells was normalized to 1 arbitrary unit. The value of each condition represents the mean ± SEM of three independent experiments. *p < 0.05 versus
basal condition.
(D) Effect of CaMKII inhibitors on insulin-stimulated [3H]-2-deoxyglucose (2DOG) uptake in 3T3-L1 adipocytes. 3T3-L1 adipocytes were either treated with DMSO
(basal) only, insulin (100 nM for 15 min) only, KN-62 (10 mM for 1 hr) only, or pretreated with KN-62 (10 mM for 45 min) prior to insulin stimulation (upper panel). In
another experiment, 3T3-L1 adipocytes were either treated with tat-ctrl (5 mM for 45 min) only, tat-CN21 (5 mM for 45 min) only, or pretreated with either of the
peptides (5 mM for 30min) prior to insulin stimulation (lower panel). The average 2DOG uptake of each condition is shown as percentage of maximum response of
insulin-treated cells and represents the mean ± SEM of three independent experiments, in which each experiment was assayed in triplicate.392 Cell Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc.
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Myo1c Phosphorylation in GLUT4 Translocationtransport in adipocytes (Figure 4D); insulin activates CaMKII in
adipocytes consistent with a recent study in rat muscle (Wright
et al., 2004); and Myo1c as an important insulin-regulated
CaMKII substrate in the fat cell. Notably, we have been unable
to observe Myo1c phosphorylation in muscle, raising the possi-
bility that an alternate myosin isoform may substitute for Myo1c
in this cell type. While we have not directly examined the effects
of insulin on intracellular Ca2+ in the adipocyte, a previous study
has shown that insulin increases the Ca2+ concentration just be-
neath the PM in isolated skeletal muscle (Bruton et al., 1999).
This raises the possibility that the insulin effect on Ca2+ homeo-
stasis may be highly localized in these cells. This may be relevant
to the effect of insulin on CaMKII activity, Myo1c phosphoryla-
tion, and the insulin-dependent release of calmodulin from
Myo1c, all of which likely occur just beneath the PM. Intriguingly,
CaMKII is activated at specific subcellular locations in other cell
types (Davies et al., 2007; Inagaki et al., 2000), whichmay explain
why there is only a modest increase in CaMKII kinase activity
induced by insulin when analyzed in vitro. This also provides
challenges in dissecting some of these steps in vivo. This is
particularly evident for the effects of insulin on the Myo1c/
calmodulin interaction, which may require the development of
highly sensitive FRET-based methods to ensure that the
changes in calmodulin binding that we have observed (Figure 2B)
are not due to changes after cell lysis. Regardless, the effect of
insulin on Myo1c/calmodulin interaction as a minimum likely
reflects reduced affinity between Myo1c and calmodulin in vivo,
thus underpinning a role for S701 phosphorylation in causing
a conformational change in Myo1c at or around IQ1. Further-
more, the observation that the IQ1A mutant caused a slight
increase in cell surface GLUT4 levels when expressed in Myo1c-
knockdown adipocytes is consistent with a role for regulated
calmodulin binding at this site.
The present study poses a number of key questions. What is
the role of Myo1c in the insulin-regulated encounter of GLUT4
vesicles with the PM? TIRFM studies indicate that a major insu-
lin-regulated step occurs proximal to the docking of vesicles with
the cell surface (Bai et al., 2007). Could Myo1c be the major reg-
ulator of this step, and if so how? Currently we can only specu-
late on this action of Myo1c, but it is intriguing that in the case of
other myosin motors an intimate relationship between myosin
function and SNARE assembly has been shown. For example,
MyoVa directly associates with the t-SNARE Syntaxin1a (Wata-
nabe et al., 2005). Hence, it will be of interest to determine how
Myo1c function intersects with SNARE assembly in the adipo-
cyte and as to whether such functions are mediated via phos-
phorylation, calmodulin release, or 14-3-3 binding. It will also
be of interest to explore the effect of insulin on cell-surface
Ca2+ channels in the adipocyte. Finally, clarifying the role of
PI3K in the insulin-dependent regulation of Ca2+ homeostasis,
CaMKII activation, and Myo1c phosphorylation will be essential
in order to determine the relationship of this pathway to the Akt
pathway.
In conclusion, Myo1c represents a novel target of insulin
action in adipocytes, and we propose the following model as
a framework for future studies. In the basal state, calmodulin
binds to the IQ1 domain of Myo1c. Upon insulin stimulation,
Ca2+ influx increases the concentration of Ca2+ just beneath
the PM, activating CaMKII, Myo1c phosphorylation at S701, andCell14-3-3 binding toMyo1c. Phosphorylation and/or 14-3-3 binding
leads to displacement of calmodulin from the Myo1c IQ1 do-
main. A key functional outcome of this pathway is increased
Myo1c ATPase activity. This likely plays a key role in GLUT4
vesicle docking and/or fusion at the plasma membrane, either
by regulating the movement of vesicles along cortical actin fila-
ments or by stabilizing the association of the vesicles and possi-
bly other proteins close to the PM, thus increasing their likelihood
of fusion.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Inhibitors
The pEYFP-Myo1c plasmid was a gift from Michael Czech (University of Mas-
sachusetts Medical School;Worcester, MA) andwas used to generate pEYFP-
Myo1c S142A, T564A, S701A, IQ1A (I706A, Q707A, R711A, and G712A),
S701AIQ1A, and K111A using the QuikChange II XL Site-Directed Mutagene-
sis Kit from Stratagene (La Jolla, CA). The pBabe-HA-GLUT4, pGEX-14-3-3b
plasmid and the mammalian expressing GST-14-3-3b plasmid was previously
described (Ramm et al., 2006). Recombinant 14-3-3b expressed as a glutathi-
one-S-transferase (GST) fusion protein in E. coli was purified by standard pro-
cedures using Glutathione-4B sepharose (GE Healthcare; Uppsala, Sweden).
The GST tag of the recombinant GST-14-3-3b protein was removed by Throm-
bin protease before coupling to CNBr-activated sepharose (GE Healthcare).
For immunoblotting and immunoprecipitation of Myo1c, previously character-
ized antibody was used (Wagner et al., 1992). Anti-14-3-3b, anti-Actin, and
anti-CaMKII antibodies were from Santa Cruz (Santa Cruz, CA). Anti-calmod-
ulin antibody was from Upstate (Lake Placid, NY). Anti-pAkt (pS473) was from
Cell Signaling Technology (Beverly, MA). Anti-pCaMKII (pT286) antibody was
from Promega (Madison, WI). Anti-GST antibody was from GE Healthcare.
Anti-HA antibody was from Covance Research Products (Richmond, CA).
Anti-GFP antibody for immunoprecipitation and western blot was from Roche
(Indianapolis, IN), and anti-GFP antibody for immunoflorescence was from
Molecular Probes (Leiden, the Netherlands). Secondary antibodies for western
blot were purchased from GE Healthcare. Alexa Fluor 488- and Cy3-conju-
gated secondary antibodies for immunoflorescence staining were fromMolec-
ular Probes and Jackson ImmunoResearch (West Grove, PA). Akt inhibitor
(Akti-1/2) was obtained from Peter Shepherd (University of Auckland, New
Zealand) and previously described (DeFeo-Jones et al., 2005). CaMKII inhibi-
tor peptide tat-CN21 and tat-ctrl were obtained fromUlrich Bayer (University of
Colorado Denver; Aurora, CO) and previously described (Vest et al., 2007).
A23187, Wortmannin, PKCz pseudosubstrate, and KN-62 were from Sigma
(Sydney, Australia). LY294002 and BAPTA-AM were purchased from Calbio-
chem (San Diego, CA).
SiRNA, Cell Culture, Cell Treatments, and Transfection
The scrambled siRNA (target sequence, 50-CAGUCGCGUUUGCGACUGG-
30), Myo1c-targeted siRNA (si-Myo1c, target sequence, 50-AAGCUUCCAGA
CAGGGAUCCAUG-30), and CaMKIId-targeted siRNA (si-CaMKIID, target
sequence, 50-GGAGUCAACUGAGAGCUCA-30) were purchased from Dhar-
macon (Lafayette, CO) and previously described (Bose et al., 2002; Ishiguro
et al., 2006). 3T3-L1 fibroblasts were cultured and differentiated into adipo-
cytes as described (Larance et al., 2005). 3T3-L1 fibroblasts were infected
with pBABE-HA-GLUT4 retrovirus as previously described (Ramm et al.,
2006). Differentiated 3T3-L1 adipocytes were transfected by electroporation
as described (Bose et al., 2002). For transfection of siRNA, 20 nmol of siRNA
was used per 10 cm dish. For cotransfection of plasmids and si-Myo1c, 100 mg
of DNA and 20 nmol of siRNA were used per 10 cm dish. CHO/IR/IRS-1 cells
were cultured and transiently transfected using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA) as described earlier (Ramm et al., 2006).
Pulldown, Immunoprecipitation, and 14-3-3 Overlay Assay
Transfected CHO/IR/IRS-1 cells, or 3T3-L1 adipocytes were incubated in se-
rum-free Dulbecco’s modified Eagle’s medium (Invitrogen) for 2 hr, stimulated
with 100 nM insulin (Calbiochem) for 15 min or preincubated with kinase inhib-
itors prior to insulin stimulation, and lysed in lysis buffer (1% Nonidet P-40,Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc. 393
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Myo1c Phosphorylation in GLUT4 TranslocationFigure 5. Phosphorylation of Myo1c Increases In Vitro ATPase Activity
(A) Effect of in vitro CaMKII phosphorylation and 14-3-3 binding on ATPase activity of Myo1c. Basal 3T3-L1 adipocyte lysates were subjected to immunoprecip-
itation with anti-Myo1c antibody and irrelevant antibody (ctrl). The immunocomplex-bound protein G sepharose was incubated with either inactive GST-CaMKII
(I) or active GST-CaMKII (A), followed by either 46 ngGST or 100 ngGST-14-3-3 for 30min at room temperature. GST-CaMKII and any unboundGST-14-3-3 were
removed by washing of the beads with ATPase reaction buffer. The precipitates were incubated with [g32P]ATP, and reactions were subjected to thin-layer
chromatography. Hydrolyzed [g32P]Pi and unhydrolyzed [g32P]ATP are indicated on the right. Immunoprecipitates were analyzed by western blot with the use
of anti-Myo1c antibody. The experiment was performed three times, and the images are from a representative experiment.
(B) Quantification of ATPase assays. The values of [g32P]Pi and [g32P]ATP were measured by densitometry. The ratio of [g32P]Pi to [g32P]ATP was calculated, and
the control signal (ctrl-IP) was subtracted. The ratio corresponding to the precipitate incubated with inactive GST-CaMKII and GST was normalized to 1 arbitrary
unit. The value of each condition represents the mean ± SEM of three independent experiments.
(C) Effect of insulin stimulation on ATPase activity of EYFP-Myo1c. CHO/IR/IRS-1 cells were transiently transfected with either EYFP (empty vector), EYFP-Myo1c
WT, or K111A. Cell lysates from either basal or insulin-treated cells were subjected to immunoprecipitation with anti-GFP antibody. The ATPase activities were
measured as described in Figure 5A. Immunoprecipitates were analyzed by western blot with the use of anti-GFP antibody. The experiment was performed three
times, and the images are from a representative experiment.394 Cell Metabolism 8, 384–398, November 5, 2008 ª2008 Elsevier Inc.
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Myo1c Phosphorylation in GLUT4 Translocation137mMNaCl, 10%glycerol, 25mMTris, pH 7.4) supplementedwith Complete
protease inhibitor mixture (Roche) and phosphatase inhibitors (2 mM sodium
orthovanadate, 1 mM pyrophosphate, 10 mM sodium fluoride) at 4C. For
Myo1c/calmodulin interaction studies, the cells were lysed in lysis buffer con-
taining 1 mMCaCl2 supplemented with EDTA-free Complete protease inhibitor
mixture (Roche) and phosphatase inhibitors. For BAPTA-AM treatment, the
cells were incubated with BAPTA-AM followed by insulin in a modified
Krebs-Ringer Phosphate buffer in which 1 mM CaCl2 was replaced by 5 mM
EGTA (120 mM NaCl, 600 mM Na2HPO4, 400 mM NaH2PO4, 6 mM KCl,
1.2mMMgSO4, 5mMEGTA, 12.5 mMHEPES, pH 7.4) and lysed in lysis buffer
supplemented with 1 mM EGTA, protease, and phosphatase inhibitors. 3T3-
L1 adipocyte fractionation was carried out as described previously (Larance
et al., 2005). Pulldown or immunoprecipitation was performed with 14-3-3-
coupled sepharose, glutathione sepharose, or specific antibodies (anti-GFP,
anti-GST, anti-Myo1c, and anti-CaMKII) coupled to protein G sepharose
(Pierce; Rockford, IL). Beads were washed with lysis buffer and PBS and
boiled in sample buffer. SDS-PAGE and western blotting was performed ac-
cording to standard protocols. The 14-3-3 overlay assaywas carried out as fol-
lows. Subsequent to SDS-PAGE, proteins were transferred to PVDF mem-
brane. For phosphatase treatment of blot prior to overlay, the blot was
incubated with alkaline phosphatase buffer (200 mM Tris, pH 8.0, 100 mM
MgCl2) containing 100 U/ml of shrimp alkaline phosphatase (Roche) at 37
C
overnight. After incubating the membrane in blocking solution (2% (w/v) BSA
in TBS/Tween 20 (0.1%, v/v)), the membrane was incubated with either GST
protein or GST-14-3-3 fusion protein in blocking solution for 1 hr, followed
by primary (anti-GST) and secondary antibody incubations.
Phosphorylation In Vivo and In Vitro
For in vivo g32P labeling, 3T3-L1 adipocytes were incubated in serum-free and
phosphate-free DMEM for 1 hr followed by serum-free DMEM containing
2.7 mCi [32P]orthophosphate per 10 cm dish for 3 hr prior to insulin stimulation.
In vitro CaMKII phosphorylation assay was performed as described (Konstan-
topoulos et al., 2007) with modifications. To activate GST-CaMKIIa fusion pro-
tein (Cell Signaling Technology), the kinase was preincubated in kinase buffer
(50 mM Tris, pH 7.5, 10 mM MgCl2, 2 mM DTT, 0.1 mM EDTA, 2 mM CaCl2,
100 mM ATP, 1.2 mM calmodulin [Sigma]) for 10 min at 30C. Inactive GST-
CaMKIIa, which was preincubated in kinase buffer in the absence of CaCl2
and calmodulin, was used as control. Immunoprecipitated Myo1c was incu-
bated with kinase buffer only, active GST-CaMKIIa or inactive GST-CaMKIIa
for 5 min at 30C. For in vitro 32P labeling of EYFP-Myo1c, 3 mCi [g32P]ATP
was added to each sample prior to CaMKII phosphorylation. The reaction
was stopped by boiling in sample buffer. The phosphorylation of Myo1c and
EYFP-Myo1c was analyzed by 14-3-3 overlay assay and autoradiography, re-
spectively. For measuring CaMKII kinase activity in 3T3-L1 adipocyte lysates,
the assay was carried out directly on the agarose beads bound with immuno-
precipitated CaMKII using SignaTECT CaMK Assay System (Promega)
according to the manufacturer’s protocol. The 32P labeling of the peptide
substrate was analyzed by scintillation counting.
In Vitro ATPase Assay
For assay of EYFP-Myo1c immunoprecipitated from CHO/IR/IRS-1 cells, the
Myo1c-bound beads were washed three times with ATPase reaction buffer
(30 mM Tris, pH 7.5, 20 mM KCl, 1 mM MgCl2, 1 mM CaCl2), and the ATPase
reactions were carried out directly on the beads in the ATPase reaction buffer
containing 100 mM actin, 500 mM ATP, and 2 mCi[g32P]ATP at 37C. For
ATPase assay after in vitro CaMKII phosphorylation of Myo1c, the CaMKII
was removed and the beads were washed three times with ATPase reaction
buffer. The beads were incubated with either 46 ng GST or 100 ng GST-
14-3-3 for 30 min. The beads were washed, and the ATPase reactions were
carried out in the presence of 1 mM tat-CN21. The reactions were stopped
by placing on ice. Three microliters of each reaction were spotted onto polye-
thyleneimine cellulose TLC plate, and the inorganic phosphate was separated
as described (Bultman et al., 2005). The amounts of [g32P]Pi and [g32P]ATP
were measured by autoradiography and quantified by densitometry.CellMass Spectrometry Analysis
Mass spectrometry identification of 14-3-3-binding proteins was performed as
described previously (Ramm et al., 2006).
Immunoflorescence Analysis
Immunoflorescence staining of HA-GLUT4-expressing 3T3-L1 adipocytes
was performed as previously described (Ramm et al., 2006). Images were
obtained using the Leica TCS SP2 confocal laser scanning microscope. A
region of interest (ROI) was set around each cell, and the amount of fluores-
cence per unit area was quantified using ImageJ software (National Institutes
of Health).
2-Deoxyglucose Uptake
3T3-L1 adipocytes were preincubated with either DMSO for 45 min, 10 mM
KN-62 for 45 min, 5 mM tat-CN21 for 30 min, or 5 mM tat-ctrl for 30 min in
KRP buffer (120 mM NaCl, 600 mM Na2HPO4, 400 mM NaH2PO4, 6 mM KCl,
1.2 mMMgSO4, 1 mM CaCl2, 12.5 mM HEPES, pH 7.4) prior to 100 nM insulin
stimulation for another 15 min. Uptake of 2DOG (Sigma) and 3H-2DOG (Perkin
Elmer Life Science; Melbourne, Australia) was measured over the final 5 min of
insulin stimulation and analyzed by scintillation counting.
Statistical Analysis
Results are given as mean ± SEM. Statistical analyses were performed by us-
ing a Student’s t test and p < 0.05was taken to indicate a significant difference.
SUPPLEMENTAL DATA
Supplemental Data include one figure and one table and can be found online at
http://www.cell.com/cellmetabolism/supplemental/S1550-4131(08)00296-9.
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